MOUNJARO 15 mg/dose KwikPen prefilled pen injector solution

2. What you need to know before you use Mounjaro KwikPen

Do not use Mounjaro KwikPen

• if you are allergic to tirzepatida or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, nurse, or pharmacist before starting Mounjaro if:

• you have severe problems with food digestion or food stays in your stomach for longer than usual (including severe gastroparesis).
• you have ever had pancreatitis (inflammation of the pancreas, which can cause severe stomach and back pain that does not go away).
• you have any eye problems (diabetic retinopathy or macular edema).
• you are taking a sulfonylurea (another diabetes medicine) or insulin for diabetes, as low blood sugar (hypoglycemia) may occur. Your doctor may need to adjust the dose of these medicines to reduce this risk.

When starting treatment with Mounjaro, you may experience fluid loss/dehydration, such as vomiting, nausea, and/or diarrhea, which can cause a decrease in kidney function. To avoid dehydration, it is essential to drink plenty of fluids. Contact your doctor if you have any questions or concerns.

If you know you are going to have surgery, inform your doctor that you are taking Mounjaro.

Children and adolescents

This medicine must not be used in children and adolescents under 18 years of age because it has not been studied in this age group.

Other medicines and Mounjaro

Tell your doctor, nurse, or pharmacist if you are using, have recently used, or might use any other medicines.

Pregnancy

If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. This medicine should not be used during pregnancy, as its effects on the fetus are unknown. Therefore, contraceptive methods are recommended while using this medicine.

Breast-feeding

It is not known whether tirzepatida passes into breast milk. A risk to newborns/babies cannot be ruled out. If you are breast-feeding or plan to breast-feed, consult your doctor before using this medicine. You and your doctor must decide whether to stop breast-feeding or stop using Mounjaro.

Driving and using machines

This medicine is unlikely to affect your ability to drive or use machines. However, if you use Mounjaro with a sulfonylurea or insulin, low blood sugar (hypoglycemia) may occur, which can reduce your ability to concentrate. Avoid driving or using machines if you have any signs of low blood sugar, such as headache, drowsiness, weakness, dizziness, hunger, confusion, irritability, rapid heartbeat, and sweating (see section 4). See section 2, "Warnings and precautions" for information on the increased risk of low blood sugar. Consult your doctor for more information.

Mounjaro KwikPen contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per dose; this is essentially "sodium-free".

Mounjaro KwikPen contains benzyl alcohol

This medicine contains 5.4 mg of benzyl alcohol in each 0.6 ml dose. Benzyl alcohol may cause allergic reactions.

Consult your doctor, nurse, or pharmacist if you are pregnant, breast-feeding, or have liver or kidney disease. This is because large amounts of benzyl alcohol can accumulate in the body and cause side effects (so-called "metabolic acidosis").

3. How to use Mounjaro KwikPen

Follow the instructions for administration of this medicine exactly as told by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

A small amount of medicine may remain in the pen after you have correctly administered all doses. Do not attempt to use the leftover medicine. After four doses, the pen should be disposed of properly.

How much to use

• The initial dose is 2.5 mg once a week for four weeks. After four weeks, your doctor will increase your dose to 5 mg once a week.

• Your doctor may increase your dose in increments of 2.5 mg up to 7.5 mg, 10 mg, 12.5 mg, or 15 mg once a week if needed. In each case, your doctor will tell you to stay on a specific dose for at least 4 weeks before moving to a higher dose.

Do not change your dose unless your doctor has told you to.

When to use Mounjaro

You can use your pen at any time of day, with or without food. If possible, you should use it on the same day each week. To help you remember when to use Mounjaro, you can write it down in a calendar if you wish.

If necessary, you can change the day of your weekly Mounjaro injection, provided that at least 3 days have passed since your last injection. After selecting a new dosing day, continue with once-weekly administration on that new day.

How to inject Mounjaro KwikPen

Mounjaro is injected under the skin (subcutaneous injection) in the abdominal area at least 5 cm away from the navel or in the upper thigh or upper arm. You may need help from another person if you want to inject into the upper arm.

If you wish, you can inject into the same area of your body each week. However, make sure to choose different injection sites within that area. If you also inject insulin, choose a different injection site for that injection.

Before using Mounjaro KwikPen, carefully read the "Instructions for use" of the pen.

Monitoring blood sugar levels

If you are using Mounjaro with a sulfonylurea or insulin, it is essential to monitor your blood sugar levels as instructed by your doctor, nurse, or pharmacist (see section 2, "Warnings and precautions").

If you use more Mounjaro than you should

If you use more Mounjaro than you should, consult your doctor immediately. Too much medicine can cause your blood sugar levels to drop too low (hypoglycemia) and may also cause nausea or vomiting.

If you forget to use Mounjaro

If you forget to inject a dose and,

• it has been 4days or less since you should have used Mounjaro, use it as soon as you remember. Then inject your next dose as usual on your scheduled day.
• it has been more than 4days since you should have used Mounjaro, skip the missed dose. Then inject your next dose as usual on your scheduled day.

Do not inject a double dose to make up for a missed dose. The minimum time between two doses must be at least 3 days.

If you stop using Mounjaro

Do not stop using Mounjaro without consulting your doctor. If you stop using Mounjaro and have type 2 diabetes, your blood sugar levels may increase.

If you have any other questions about using this medicine, ask your doctor, nurse, or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Uncommon(may affect up to 1 in 100 people)

• Pancreatitis (inflammation of the pancreas) that could cause severe stomach and back pain that does not go away. See your doctor immediately if you experience these symptoms.

Rare(may affect up to 1 in 1,000 people)

• Severe allergic reactions (e.g., anaphylactic reaction, angioedema). You should get medical help immediately and inform your doctor if you experience symptoms such as breathing problems, rapid swelling of the lips, tongue, and/or throat with difficulty swallowing, and rapid heartbeat.

Other side effects

Very common(may affect more than 1 in 10 people)

• Nausea
• Diarrhea
• Stomach pain (abdominal pain) reported in patients treated for weight control
• Vomiting reported in patients treated for weight control
• Constipation reported in patients treated for weight control

These side effects are usually not serious. Nausea, diarrhea, and vomiting are more common when starting tirzepatida but decrease over time in most patients.

• Low blood sugar (hypoglycemia) is very common when tirzepatida is used with a sulfonylurea and/or insulin. If you are taking a sulfonylurea or insulin for type 2 diabetes, you may need to have your dose reduced while using tirzepatida (see section 2, "Warnings and precautions"). Symptoms of low blood sugar can include headache, drowsiness, weakness, dizziness, hunger, confusion, irritability, rapid heartbeat, and sweating. Your doctor should tell you how to treat low blood sugar levels.

Common(may affect up to 1 in 10 people)

• Low blood sugar (hypoglycemia) when tirzepatida is used for type 2 diabetes with metformin and a sodium-glucose cotransporter 2 inhibitor (another diabetes medicine)
• Allergic reaction (hypersensitivity) (e.g., rash, itching, and eczema)
• Dizziness reported in patients treated for weight control
• Low blood pressure reported in patients treated for weight control

• Decreased appetite reported in patients treated for type 2 diabetes
• Stomach pain (abdominal pain) reported in patients treated for type 2 diabetes
• Vomiting reported in patients treated for type 2 diabetes – usually decreases over time
• Indigestion (dyspepsia)
• Constipation reported in patients treated for type 2 diabetes
• Bloating
• Belching
• Gas (flatulence)
• Acid reflux or heartburn (also called gastroesophageal reflux disease – GERD) – a disease caused by stomach acid flowing back up into the tube that connects the stomach to the mouth

• Hair loss reported in patients treated for weight control
• Fatigue
• Injection site reactions (e.g., itching or redness)
• Rapid heartbeat

• Increased levels of pancreatic enzymes (such as lipase and amylase) in the blood.
• Increased levels of calcitonin in the blood in patients treated for weight control.

Uncommon(may affect up to 1 in 100 people)

• Low blood sugar (hypoglycemia) when tirzepatida is used with metformin for type 2 diabetes
• Gallstones
• Gallbladder inflammation
• Weight loss reported in patients treated for type 2 diabetes
• Pain at the injection site
• Increased levels of calcitonin in the blood in patients treated for type 2 diabetes or for OSA with obesity
• Altered sense of taste
• Changes in skin sensitivity
• Delayed stomach emptying

Reporting of side effects

If you experience any side effects, talk to your doctor, nurse, or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Mounjaro KwikPen

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label of the pen and on the carton after EXP. The expiry date is the last day of the month shown.

Store in a refrigerator (2°C to 8°C). Do not freeze. If the pen has been frozen, DO NOT USE IT.

Mounjaro KwikPen can be stored without refrigeration below 30°C for a maximum of 30 days after first use, and then the pen must be discarded.

Do not use this medicine if you notice that the pen is damaged or the medicine is cloudy, has color, or contains particles.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Contents and Additional Information

Composition of Mounjaro KwikPen

The active ingredient is tirzepatide.

Mounjaro 2.5mg/doseKwikPen:Each dose contains 2.5 mg of tirzepatide in 0.6 ml of solution. Each pre-filled multidose pen contains 10 mg of tirzepatide in 2.4 ml (4.17 mg/ml). Each pen delivers 4 doses of 2.5 mg.

Mounjaro 5mg/doseKwikPen:Each dose contains 5 mg of tirzepatide in 0.6 ml of solution. Each pre-filled multidose pen contains 20 mg of tirzepatide in 2.4 ml (8.33 mg/ml). Each pen delivers 4 doses of 5 mg.

Mounjaro 7.5mg/doseKwikPen:Each dose contains 7.5 mg of tirzepatide in 0.6 ml of solution. Each pre-filled multidose pen contains 30 mg of tirzepatide in 2.4 ml (12.5 mg/ml). Each pen delivers 4 doses of 7.5 mg.

Mounjaro 10mg/doseKwikPen:Each dose contains 10 mg of tirzepatide in 0.6 ml of solution. Each pre-filled multidose pen contains 40 mg of tirzepatide in 2.4 ml (16.7 mg/ml). Each pen delivers 4 doses of 10 mg.

Mounjaro 12.5mg/doseKwikPen:Each dose contains 12.5 mg of tirzepatide in 0.6 ml of solution. Each pre-filled multidose pen contains 50 mg of tirzepatide in 2.4 ml (20.8 mg/ml). Each pen delivers 4 doses of 12.5 mg.

Mounjaro 15mg/doseKwikPen:Each dose contains 15 mg of tirzepatide in 0.6 ml of solution. Each pre-filled multidose pen contains 60 mg of tirzepatide in 2.4 ml (25 mg/ml). Each pen delivers 4 doses of 15 mg.

The other components are disodium hydrogen phosphate heptahydrate (E339), benzyl alcohol (E1519) (see section 2 "Mounjaro KwikPen contains benzyl alcohol" for more information), glycerol, phenol, sodium chloride, and sodium hydroxide (see section 2 "Mounjaro contains sodium" for more information); concentrated hydrochloric acid and water for injectable preparations.

Appearance of the Product and Container Contents

Mounjaro is a clear, colorless to slightly yellowish injectable solution in a pre-filled pen (KwikPen).

Each KwikPen contains 2.4 ml of injectable solution (4 doses of 0.6 ml) and excess for purging.

Needles are not included.

Package sizes of 1 and 3 KwikPens.

Only some package sizes may be marketed.

Marketing Authorization Holder

Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Netherlands.

Manufacturer

Eli Lilly Italia S.p.A., Via Gramsci 731/733, 50019, Sesto Fiorentino, Florence (FI), Italy

Lilly S.A., Avda. de la Industria, 30, 28108 Alcobendas, Madrid, Spain

Lilly France, 2, rue du Colonel Lilly, 67640 Fegersheim, France

Millmount Healthcare Limited, Block 7 City North Business Campus, Stamullen, K32 YD60, Ireland

Millmount Healthcare Limited, IDA Science And Technology Park, Mullagharlin, Dundalk, Co. Louth, A91 DET0, Ireland

You can request more information about this medicine by contacting the local representative of the marketing authorization holder:

Date of Last Revision of this Prospectus:

Other Sources of Information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu, and on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).

Important Information You Should Know Before Injecting Mounjaro KwikPen.

Read these instructions for use and the prospectus before starting to inject Mounjaro KwikPen and each time you get a new pen. There may be new information. This information does not replace the conversation with your doctor, nurse, or pharmacist about your medical condition or treatment.

Mounjaro KwikPen is a pre-filled multidose pen. The pen contains 4 fixed doses, one dose administered weekly.Inject one single injection weekly, under the skin (subcutaneously).

After 4 doses, discard (throw away) the pen, including any unused medicine. The pen will prevent you from dialing a full dose after 4 weekly doses have been administered. Do notinject the leftover medicine. Do not transfer the medicine from the pen to a syringe.

Do notshare your Mounjaro KwikPen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.

Blind or visually impaired people should not use the pen without the help of a trained person to use it.

Parts Guide

Parts of Mounjaro KwikPen

Materials Needed for Injection

• Mounjaro KwikPen
• Needle compatible with KwikPen (If you do not know which needle to use for the pen, talk to your healthcare professional)
• Cotton swab, gauze, or cotton ball
• Container for disposing of sharp objects or household container

Preparation for Injecting Mounjaro KwikPen

Injecting Mounjaro KwikPen

After Your Mounjaro KwikPen Injection

• Country of registration
  Spain
• Active substance
  tirzepatide
• Prescription required
  Yes
• Manufacturer
  Eli Lilly Nederland B.V.
• This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
• Alternatives to MOUNJARO 15 mg/dose KwikPen prefilled pen injector solution
  

  MOUNJARO 10 mg PRE-FILLED PEN INJECTION SOLUTION

  Dosage form:  INJECTABLE, 10 mg

  Active substance:  tirzepatide

  Manufacturer:  Eli Lilly Nederland B.V.

  Prescription required

  

  MOUNJARO 10 mg INJECTABLE SOLUTION IN VIAL

  Dosage form:  INJECTABLE, 10 mg

  Active substance:  tirzepatide

  Manufacturer:  Eli Lilly Nederland B.V.

  Prescription required

  

  MOUNJARO 10 mg/dose KwikPen prefilled pen injector solution

  Dosage form:  INJECTABLE, 10 mg/dose

  Active substance:  tirzepatide

  Manufacturer:  Eli Lilly Nederland B.V.

  Prescription required

Online doctors for MOUNJARO 15 mg/dose KwikPen prefilled pen injector solution

Discuss questions about MOUNJARO 15 mg/dose KwikPen prefilled pen injector solution, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (3)

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

• seasonal and perennial allergies
• allergic rhinitis and chronic nasal symptoms
• asthma and breathing difficulties
• food and medication allergies
• urticaria, atopic dermatitis and skin reactions
• recurrent infections in children
• sports-related health questions
• general family medicine concerns

Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.

Book a video appointment

€80

5.0 (9)

Iryna Reznychenko

Gynecology 26 years exp.

Dr Iryna Reznychenko is an obstetrician-gynaecologist, paediatric gynaecologist, and certified lactation consultant. She provides online consultations for women at all stages of life – from adolescence to menopause. Her work combines medical care for gynaecological conditions with dedicated support for breastfeeding challenges, both physical and emotional.

Areas of expertise:

• interpretation of test results and personalised treatment planning
• menstrual irregularities, PCOS, endometriosis
• abnormal uterine bleeding, endometrial hyperplasia, cervical dysplasia
• care during perimenopause and menopause, hormonal balance, cancer prevention
• breastfeeding issues: nipple pain, cracked skin, blocked ducts, low milk supply
• support during the postpartum and lactation period

Dr Reznychenko offers a clear, attentive and professional approach. Her consultations help prevent minor discomforts from developing into more serious concerns – all in a convenient online format.

Book a video appointment

€55

5.0 (11)

Mar Tabeshadze

Endocrinology 11 years exp.

Dr. Mar Tabeshadze is a licensed endocrinologist and general practitioner in Spain. She provides online consultations for adults, offering medical support for a wide range of endocrine conditions and related health concerns.

• Diagnostic consultations for suspected endocrine disorders
• Management of thyroid conditions, including in pregnant women
• Early detection and treatment of type 1 and type 2 diabetes, with personalised therapy plans
• Obesity treatment: identifying underlying causes of weight gain, combining medication and non-pharmacological strategies, and long-term support
• Diagnosis and treatment of endocrine-related skin, hair, and nail issues
• Ongoing care for patients with osteoporosis, pituitary, and adrenal gland disorders

Dr. Tabeshadze takes a patient-centred approach based on evidence-based medicine. Her goal is to help patients achieve hormonal balance, manage chronic conditions effectively, and improve overall well-being through targeted, personalised care.

Book a video appointment

€55

5.0 (29)

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

• High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
• Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
• Leg swelling, chronic fatigue, reduced exercise tolerance.
• EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
• Post-COVID-19 cardiac monitoring and care.

Endocrinology – Diabetes, thyroid, metabolism:

• Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
• Individual treatment plans including oral medications and insulin therapy.
• GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
• Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
• Metabolic syndrome – obesity, lipid disorders, insulin resistance.

Gastroenterology – Digestive health:

• Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
• Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
• Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).

General internal medicine and preventive care:

• Respiratory infections – cough, colds, bronchitis.
• Lab test analysis, therapy adjustments, medication management.
• Adult vaccinations – planning, contraindications assessment.
• Cancer prevention – screening strategies and risk assessment.
• Holistic approach – symptom relief, complication prevention, and quality of life improvement.

Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.

Book a video appointment

€60

5.0 (29)

Dmytro Horobets

Family medicine 7 years exp.

Dr. Dmytro Horobets is a licensed family medicine physician in Poland, specialising in endocrinology, diabetology, obesity management, gastroenterology, pediatrics, general surgery, and pain medicine. He offers online consultations for adults and children, providing personalised medical support for a wide range of acute and chronic health concerns.

Areas of expertise:

• Endocrinology: diabetes type 1 and type 2, prediabetes, thyroid disorders, metabolic syndrome, hormonal imbalance.
• Obesity medicine: structured weight management plans, nutritional counselling, obesity-related health risks.
• Gastroenterology: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), liver and biliary conditions.
• Pediatric care: infections, respiratory symptoms, digestive issues, growth and development monitoring.
• General surgery support: pre- and post-surgical consultations, wound care, rehabilitation.
• Pain management: chronic and acute pain, back pain, joint pain, post-traumatic pain syndromes.
• Cardiovascular health: hypertension, cholesterol control, risk assessment for heart disease.
• Preventive medicine: regular check-ups, health screenings, long-term management of chronic conditions.

Dr. Horobets combines evidence-based medicine with a patient-centred approach. He carefully evaluates each patient’s medical history and symptoms, offering clear explanations and structured treatment plans adapted to individual needs.

Whether you need help managing diabetes, tackling weight-related health issues, interpreting lab results, or receiving general family medicine support, Dr. Horobets provides professional online care tailored to your specific health goals.

Book a video appointment

€60

0.0 (2)

Marianna Neshta

Endocrinology 25 years exp.

Marianna Neshta is a medical doctor specialising in endocrinology and ultrasound diagnostics. She provides online consultations for adults, focusing on the diagnosis, treatment, and long-term management of endocrine disorders. Her approach includes personalised care plans, analysis of lab results and ultrasound scans, and evidence-based treatment.

Key areas of expertise:

• Type 1 and Type 2 diabetes – diagnosis, therapy adjustment, CGM interpretation, and prevention of chronic complications
• Obesity – treatment using both medication and lifestyle strategies, including modern GLP-1 medications and tailored follow-up plans
• Thyroid disorders – ultrasound assessment, treatment planning, and management during pregnancy
• Male hypogonadism – age-related or hormonal, including diagnostics and therapy
• Metabolic syndrome, prediabetes, lipid disorders – risk assessment, lifestyle recommendations, and medical treatment
• Calcium metabolism disorders – diagnosis and management of osteoporosis, hyperparathyroidism, and hypoparathyroidism

Dr Neshta applies current clinical guidelines and diagnostic tools, offering medical support adapted to each patient’s individual needs — all in an accessible online format.

Book a video appointment

€45

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Suscribirse

Acepto recibir correos electrónicos de marketing y acepto la Política de Privacidad y los Términos de Uso.

Follow us on social media